Oslo, 4 January 2021: Reference is made to Navamedic ASA's ("Navamedic" or the
"Company") stock exchange announcement published on 4 August 2020 regarding the
completion of the transaction with ACS Dobfar and InfoRLife for the acquisition
of marketing authorisations for a series of antibiotics for hospital use in the
Nordic region (the "Transaction").

The board of directors of Navamedic has today, on 4 January 2021, pursuant to
the authorisation granted to it by the extraordinary general meeting held on 11
March 2020, resolved to settle the first tranche of the purchase price in the
Transaction for an amount of NOK 19 million by issuance of 1,053,775 new shares
to InfoRLife. The resolution to issue the 1,053,775 new shares entails an
increase of the Company's share capital of NOK 779,793.50. 

The subscription price for the new shares is NOK 18.0304 per share, which
corresponds to the volume weighted average trading price of the Navamedic shares
from 24 January to 6 February 2020, being the 10 last trading days prior to, but
not including, Navamedic's stock exchange announcement published on 7 February
2020. 

Following the registration of the share capital increase with the Norwegian
Register of Business Enterprises (Nw. Foretaksregisteret), the Company's new
share capital is 12,095,788.40, divided into 16,345,660 shares, each with a par
value of NOK 0.74.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

About Navamedic

Navamedic ASA is a full-service provider of high-quality healthcare products to
hospitals and pharmacies. Navamedic meets the specific medical needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in the UK and
Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA). For more information, please visit www.navamedic.com
This information is subject to the disclosure requirements pursuant to the
issuer rules for Oslo Børs.